Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains

Anticalin(®) proteins have been proven as versatile clinical stage biotherapeutics. Due to their small size (∼20 kDa), they harbor a short intrinsic plasma half-life which can be extended, e.g., by fusion with IgG or Fc. However, for antagonism of co-immunostimulatory Tumor Necrosis Factor Receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegemund, Martin, Oak, Prajakta, Hansbauer, Eva-Maria, Allersdorfer, Andrea, Utschick, Karoline, Winter, Alexandra, Grasmüller, Christina, Galler, Gunther, Mayer, Jan-Peter, Weiche, Benjamin, Prassler, Josef, Kontermann, Roland E., Rothe, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573339/
https://www.ncbi.nlm.nih.gov/pubmed/34759826
http://dx.doi.org/10.3389/fphar.2021.759337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573339/
https://www.ncbi.nlm.nih.gov/pubmed/34759826
http://dx.doi.org/10.3389/fphar.2021.759337

Ejemplares similares